“We are encouraged by the continued progress in the development of our lead asset, OKI-219, as we have completed the enrollment of the single agent and the fulvestrant combination arms and have initiated two new triplet arms. Given the clinical performance of OKI-219 to date, we are eager to move broad and deep in both HR+ and HER2+ breast cancer with OKI-219,” said Nick Saccomano, president and CEO of OnKure.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OKUR: